Skip to main content
SpringerLink
Log in

Antioxidants and atherosclerosis: Emerging drug therapies

  • Published:
Current Atherosclerosis Reports Aims and scope Submit manuscript

Abstract

Inflammation has a fundamental role in mediating all stages of atherosclerotic disease. The key role of oxidation in linking lipids and inflammation to atherosclerosis is compelling and supported by experimental evidence. However, the relevance of the antioxidant hypothesis for the treatment of patients with atherosclerosis has not been definitively proven. Probucol has reduced post-percutaneous coronary intervention (PCI) restenosis and progression of carotid atherosclerosis in clinical trials. The antioxidant/vascular protectant AGI-1067 has also been effective at preventing atherosclerosis in all tested animal models. The nonintervened reference coronary segments of the PCI vessel demonstrated improvements with AGI-1067 in the Canadian Antioxidant Restenosis Trial-1 (CART-1), evidence supportive of a clinical effect on slowing atherosclerosis progression. Results of randomized trials with the “antioxidant” vitamins have been disappointing, but there are potentially important problems associated with their use, including their potential pro-oxidant effects. Two important trials that test the antioxidant/anti-inflammatory hypothesis are ongoing with AGI-1067: CART-2, which assesses its value for the reduction of both atherosclerosis progression in non-PCI vessels and post-PCI restenosis; and Aggressive Reduction of Inflammation Stops Events (ARISE), which is evaluating the effects of AGI-1067 on hard cardiovascular outcomes.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

  1. Ross R: Atherosclerosis—an inflammatory disease. N Engl J Med 1999, 340:115–126.

    Article  PubMed  CAS  Google Scholar 

  2. Kunsch C, Medford RM: Oxidative stress as a regulator of gene expression in the vasculature. Circ Res 1999, 85:753–766.

    PubMed  CAS  Google Scholar 

  3. Cushing SD, Berliner JA, Valente AJ, et al.: Minimally modified low density lipoprotein induces monocyte chemotactic protein 1 in human endothelial cells and smooth muscle cells. Proc Natl Acad Sci USA 1990, 87:5134–5138.

    Article  PubMed  CAS  Google Scholar 

  4. Marui N, Offermann MK, Swerlick R, et al.: Vascular cell adhesion molecule-1 (VCAM-1) gene transcription and expression are regulated through an antioxidant-sensitive mechanism in human vascular endothelial cells. J Clin Invest 1993, 92:1866–1874.

    Article  PubMed  CAS  Google Scholar 

  5. Rajavashisth TB, Andalibi A, Territo MC, et al.: Induction of endothelial cell expression of granulocyte and macrophage colony-stimulating factors by modified low-density lipoproteins. Nature 1990, 344:254–257.

    Article  PubMed  CAS  Google Scholar 

  6. Bourcier T, Sukhova G, Libby P: The nuclear factor kappa-B signaling pathway participates in dysregulation of vascular smooth muscle cells in vitro and in human atherosclerosis. J Biol Chem 1997, 272:15817–15824.

    Article  PubMed  CAS  Google Scholar 

  7. Thomas CE, Jackson RL, Ohlweiler DF, et al.: Multiple lipid oxidation products in low density lipoproteins induce interleukin-1 beta release from human blood mononuclear cells. J Lipid Res 1994, 35:417–427.

    PubMed  CAS  Google Scholar 

  8. Rajagopalan S, Meng XP, Ramasamy S, et al.: Reactive oxygen species produced by macrophage-derived foam cells regulate the activity of vascular matrix metalloproteinases in vitro. J Clin Invest 1996, 98:2572–2579.

    Article  PubMed  CAS  Google Scholar 

  9. Ikeda H, Koga Y, Oda T, et al.: Free oxygen radicals contribute to platelet aggregation and cyclic flow variations in stenosed and endothelium-injured canine coronary arteries. J Am Coll Cardiol 1994, 24:1749–1756.

    Article  PubMed  CAS  Google Scholar 

  10. Roberts MJ, Young IS, Trouton TG, et al.: Transient release of lipid peroxides after coronary artery balloon angioplasty. Lancet 1990, 336:143–145.

    Article  PubMed  CAS  Google Scholar 

  11. Iuliano L, Pratico D, Greco C, et al.: Angioplasty increases coronary sinus F2-isoprostane formation: evidence for in vivo oxidative stress during PTCA. J Am Coll Cardiol 2001, 37:76–80.

    Article  PubMed  CAS  Google Scholar 

  12. Kugiyama K, Kerns SA, Morissett JD, et al.: Impairment of endothelium-dependent arterial relaxation by lysolecithin in modified low-density lipoproteins. Nature 1990, 344:160–162.

    Article  PubMed  CAS  Google Scholar 

  13. Tardif JC, Grégoire J, Bourassa MG: Antioxidants and restenosis—human studies. In Antioxidants and Cardiovascular Disease. Edited by Tardif JC, Bourassa MG. Amsterdam: Kluwer; 2000:175–194.

    Google Scholar 

  14. Christen WG, Hennekens CH: Antioxidant vitamins and cardiovascular disease: evidence from observational epidemiologic studies and randomized trials. In Antioxidants and Cardiovascular Disease. Edited by Tardif JC and Bourassa MG. Amsterdam: Kluwer; 2000:135–144.

    Google Scholar 

  15. The Alpha-Tocopherol, Beta-Carotene Cancer Prevention Study Group: The effect of vitamin E and beta carotene on the incidence of lung cancer and other cancers in male smokers. N Engl J Med 1994, 330:1029–1035.

    Article  Google Scholar 

  16. Omenn GS, Goodman GE, Thornquist MD, et al.: Effects of a combination of beta carotene and vitamin A on lung cancer and cardiovascular disease. N Engl J Med 1996, 334:1150–1155.

    Article  PubMed  CAS  Google Scholar 

  17. Stephens NG, Parsons A, Schofield PM, et al.: Randomized controlled trial of vitamin E in patients with coronary disease: Cambridge Heart Antioxidant Study (CHAOS). Lancet 1996, 347:781–786.

    Article  PubMed  CAS  Google Scholar 

  18. Gruppo Italiano per lo Studio della Sopravivenza nell’Infarcto miocardico: Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSI-Prevenzione trial. Lancet 1999, 354:447–455.

  19. The HOPE Study Investigators: Vitamin E supplementation and cardiovascular events in high-risk patients. N Engl J Med 2000, 342:154–160.

    Article  Google Scholar 

  20. MRC/BHF Heart Protection Study Collaborative Group: MRC/BHF heart protection study of cholesterol-lowering therapy and of antioxidant vitamin supplementation in a wide range of patients at increased risk of coronary heart disease death: early safety and efficacy experience. Eur Heart J 1999, 20:725–741.

    Article  Google Scholar 

  21. Bowry VW, Ingold KU, Stocker R: Vitamin E in human low-density lipoprotein: when and how this antioxidant becomes a pro-oxidant. Biochem J 1992, 288:341–344.

    PubMed  CAS  Google Scholar 

  22. Keaney JF Jr, Gaziano JM, Xu A, et al.: Low-dose alpha-tocopherol improves and high-dose alpha-tocopherol worsens endothelial vasodilator function in cholesterol-fed rabbits. J Clin Invest 1994, 93:844–851.

    Article  PubMed  Google Scholar 

  23. Waters DD, Alderman EL, Hsia, J, et al.: Effects of hormone replacement therapy and antioxidant vitamin supplements on coronary atherosclerosis in postmenopausal women: a randomized controlled trial. JAMA 2002, 288:2432–2440.

    Article  PubMed  CAS  Google Scholar 

  24. Tardif JC, Côté G, Lespérance J, et al.: Probucol and multi-vitamins in the prevention of restenosis after coronary angioplasty. N Engl J Med 1997, 337:365–372.

    Article  PubMed  CAS  Google Scholar 

  25. Brown BG, Zhao XQ, Chait A, et al.: Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease. N Engl J Med 2001, 345:1583–1592.

    Article  PubMed  CAS  Google Scholar 

  26. Rodés J, Tardif JC, Lespérance J, et al.: Prevention of restenosis after angioplasty in small coronary arteries with probucol. Circulation 1998, 97:429–436.

    PubMed  Google Scholar 

  27. Côté G, Tardif JC, Lespérance J, et al.: Effects of probucol on vascular remodeling after coronary angioplasty. Circulation 1999, 99:30–35.

    PubMed  Google Scholar 

  28. Ferns GA, Forster L, Stewart-Lee A, et al.: Probucol inhibits neointimal thickening and macrophage accumulation after balloon injury in the cholesterol-fed rabbit. Proc Natl Acad Sci U S A 1992, 89:11312–11316.

    Article  PubMed  CAS  Google Scholar 

  29. Schneider JE, Berk BC, Gravanis MB, et al.: Probucol decreases neointimal formation in a swine model of coronary artery balloon injury: a possible role for antioxidants in restenosis. Circulation 1993, 88:628–637.

    PubMed  CAS  Google Scholar 

  30. Freyschuss A, Stiko-Rahm A, Swedenborg J, et al.: Antioxidant treatment inhibits the development of intimal thickening after balloon injury of the aorta in hypercholesterolemic rabbits. J Clin Invest 1993, 91:1282–1288.

    Article  PubMed  CAS  Google Scholar 

  31. Nunes GL, Sgoutas DS, Redden RA, et al.: Combination of vitamins C and E alters the response to coronary balloon injury in the the pig. Arterioscler Thromb Vasc Biol 1995, 15:156–165.

    PubMed  CAS  Google Scholar 

  32. Lafont A, Vinchon F, Addad F, et al.: Antioxidants and restenosis: animal studies. In Antioxidants and Cardiovascular Disease. Edited by Tardif JC, Bourassa MG. Amsterdam: Kluwer; 2000:161–174.

    Google Scholar 

  33. Lau AK, Leichtweis SB, Hume P, et al.: Probucol promotes functional reendothelialization in balloon-injured rabbit aortas. Circulation 2003, 107:2031–2036.

    Article  PubMed  CAS  Google Scholar 

  34. Setsuda M, Inden M, Hiraoka N, et al.: Probucol therapy in the prevention of restenosis after successful percutaneous transluminal coronary angioplasty. Clin Ther 1993, 15:374–381.

    PubMed  CAS  Google Scholar 

  35. Watanabe K, Sekyia M, Ikeda S, et al.: Preventive effects of probucol on restenosis after percutaneous transluminal coronary angioplasty. Am Heart J 1996, 132:23–29.

    Article  PubMed  CAS  Google Scholar 

  36. Lee YJ, Daida H, Yokoi H, et al.: Effectiveness of probucol in preventing restenosis after percutaneous transluminal coronary angioplasty. Jpn Heart J 1996, 37:327–332.

    PubMed  CAS  Google Scholar 

  37. Tardif JC, Côté G, Lespérance J, et al.: Impact of residual plaque burden after balloon angioplasty in the MultiVitamins and Probucol (MVP) trial. Can J Cardiol 2001, 17:49–55.

    PubMed  CAS  Google Scholar 

  38. Yokoi H, Daida H, Kuwabara Y, et al.: Effectiveness of an antioxidant in preventing restenosis after percutaneous transluminal coronary angioplasty: The Probucol Angioplasty Restenosis Trial. J Am Coll Cardiol 1997, 30:855–862.

    Article  PubMed  CAS  Google Scholar 

  39. Tardif JC, Gregoire J, Schwartz L, et al.: Effects of AGI-1067 and probucol after percutaneous coronary interventions. Circulation 2003, 107:552–558.

    Article  PubMed  CAS  Google Scholar 

  40. Meng CQ, Somers PK, Rachita CL, et al.: Novel phenolic antioxidants as multifunctional inhibitors of inducible VCAM-1 expression for use in atherosclerosis. Bioorg Med Chem Lett 2002, 12:2545–2548.

    Article  PubMed  CAS  Google Scholar 

  41. Wasserman MA, Sundell CL, Kunsch C, et al.: Chemistry and pharmacology of vascular protectants: a novel approach to the treatment of atherosclerosis and coronary artery disease. Am J Cardiol 2003, 91(Suppl):34A-40A.

    Article  PubMed  CAS  Google Scholar 

  42. Kunsch C, Luchoomun J, Grey JY, et al.: Selective inhibition of endothelial and monocyte redox-sensitive genes by AGI-1067: a novel antioxidant and anti-inflammatory agent. J Pharmacol Exp Ther 2004, 308:820–829.

    Article  PubMed  CAS  Google Scholar 

  43. Sundell CL, Somers PK, Meng CQ, et al.: AGI-1067: a multi-functional phenolic antioxidant, lipid modulator, anti-inflammatory and antiatherosclerotic agent. J Pharmacol Exp Ther 2003, 305:1116–1123.

    Article  PubMed  CAS  Google Scholar 

  44. Anderson TJ, Meredith IT, Yeung AC, et al.: The effect of cholesterol-lowering and antioxidant therapy on endothelium-dependent coronary vasomotion. N Engl J Med 1995, 332:488–493.

    Article  PubMed  CAS  Google Scholar 

  45. McLean LR, Thomas CE, Weintraub B, et al.: Modulation of the physical state of cellular cholesteryl esters by probucol. J Biol Chem 1992, 267:12291–12298.

    PubMed  CAS  Google Scholar 

  46. Tardif JC: Clinical results with AGI-1067: a novel antioxidant vascular protectant. Am J Cardiol 2003, 91(Suppl):41A-49A.

    Article  PubMed  CAS  Google Scholar 

  47. Sawayama Y, Shinizu C, Maeda N, et al.: Effects of probucol and pravastatin on common carotid atherosclerosis in patients with asymptomatic hypercholesterolemia. J Am Coll Cardiol 2002, 39:610–616.

    Article  PubMed  CAS  Google Scholar 

  48. Walldius G, Erikson U, Olsson AG, et al.: The effect of probucol on femoral atherosclerosis: the Probucol Quantitative Regression Swedish Trial (PQRST). Am J Cardiol 1994, 74:875–883.

    Article  PubMed  CAS  Google Scholar 

  49. Sasahara M, Raines EW, Chait A, et al.: Inhibition of hypercholesterolemia-induced atherosclerosis in the non-human primate by probucol. Is the extent of atherosclerosis related to resistance of LDL to oxidation? J Clin Invest 1994, 94:155–164.

    Article  PubMed  CAS  Google Scholar 

  50. Guedes A, Tardif JC: Intravascular ultrasound assessment of atherosclerosis. Curr Atheroscler Rep 2004, 6:219–224.

    Article  PubMed  Google Scholar 

  51. Nunes GL, Robinson K, Kalynych A, et al.: Vitamins C and E inhibit O2- production in the pig coronary artery. Circulation 1997, 96:3593–3601.

    PubMed  CAS  Google Scholar 

  52. Tardif JC, Gregoire J, L’Allier PL: Prevention of restenosis with antioxidants. Mechanisms and implications. Am J Cardiovasc Drugs 2002, 2:323–334.

    Article  PubMed  CAS  Google Scholar 

  53. Tardif JC: Insights into oxidative stress and atherosclerosis. Can J Cardiol 2000, 16(Suppl D):2D-4D.

    PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. MHI Research Center, Montreal Heart Institute, 5000 Belanger Street, H1T 1C8, Montreal, Quebec, Canada

    Jean-Claude Tardif MD, FRCPC

Authors
  1. Jean-Claude Tardif MD, FRCPC
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Tardif, JC. Antioxidants and atherosclerosis: Emerging drug therapies. Curr Atheroscler Rep 7, 71–77 (2005). https://doi.org/10.1007/s11883-005-0078-1

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11883-005-0078-1

Keywords

Search

Navigation